| |
Analyte |
Species |
Matrix |
LLOQ- ULOQ |
Validated Sample Vol. (mL) |
Method |
Anti- coagulant |
| V |
1'-Hydroxymidazolam |
Human |
P |
0.100- 100 ng/mL |
0.200 |
LC- MS/MS |
2, 5, 6 |
| V |
1'-Hydroxymidazolam |
Human |
P |
0.100- 100 ng/mL |
0.400 |
LC- MS/MS |
2, 6 |
| V |
2'difluoro-2', 2'-deoxyuridine (dFdU) |
Human |
P |
50.0- 50,000 ng/mL |
0.050 |
LC- MS/MS |
2, 6 |
| V |
2-Hydroxydesipramine |
Human |
P |
0.250- 100 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
4-Hydroxydiclofenac |
Human |
P |
5.00- 2,500 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
4-Hydroxymidazolam |
Human |
P |
0.100- 100 ng/mL |
0.400 |
LC- MS/MS |
2, 6 |
| V |
5-Aminosalicylic Acid |
Human |
P |
0.0250- 2.50 µg/mL |
0.025 |
LC- MS/MS |
6 |
| V |
5-Hydroxyindole-3-acetic acid (5-HIAA) |
Human |
P |
1.00- 200 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
5-Hydroxyomeprazole |
Human |
P |
2.50- 2,500 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
5-Hydroxyomeprazole |
Human |
P |
0.500- 1,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
6-beta-hydroxycortisol |
Human |
U |
50.0- 10,000 ng/mL |
0.025 |
LC- MS/MS |
N |
| V |
6-beta-hydroxycortisol |
Human |
U |
5.00- 1,000 ng/mL |
0.050 |
LC- MS/MS |
N |
| V |
7-Hydroxymethotrexate |
Human |
P |
1.00- 250 ng/mL |
0.050 |
LC- MS/MS |
5 |
| V |
Abacavir |
|
P |
2.50- 5,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Acetaminophen |
Dog |
DBS |
0.100- 50.0 µg/mL |
0.030 |
LC- MS/MS |
2 |
| R |
Acetaminophen |
Dog |
P |
0.100- 50.0 µg/mL |
0.025 |
LC- MS/MS |
2 |
| R |
Acetaminophen |
Rat |
P |
0.100- 50.0 µg/mL |
0.025 |
LC- MS/MS |
2 |
| V |
Acetaminophen |
Rat |
DBS |
0.100- 50.0 µg/mL |
0.030 |
LC- MS/MS |
2 |
| V |
Acetaminophen |
Rat |
WB |
0.100- 50.0 µg/mL |
0.025 |
LC- MS/MS |
2 |
| V |
Acetaminophen |
Rat |
WB |
0.100- 50.0 µg/mL |
0.020 |
LC- MS/MS |
2 |
| V |
Acetaminophen |
Human |
P |
50.0- 50,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Adefovir |
Human |
S |
1.00- 200 ng/mL |
0.100 |
LC- MS/MS |
N |
| V |
Adefovir |
Human |
P |
0.250- 50.0 ng/mL |
0.150 |
LC- MS/MS |
2 |
| V |
Albuterol |
Human |
S |
50.0- 10,000 pg/mL |
0.400 |
LC- MS/MS |
N |
| V |
Aldosterone |
Human |
P |
10.0- 5,000 pg/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Alprazolam |
Human |
P |
0.100- 50.0 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Alprazolam |
Human |
P |
0.100- 100 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Amlodipine |
Human |
P |
0.0500- 25.0 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Amphetamine |
Human |
P |
0.100- 50.0 ng/mL |
0.250 |
LC- MS/MS |
5 |
| V |
Amprenavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Amprenavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Amrubicin |
Human |
P |
2.00- 2,000 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Amrubicinol |
Human |
P |
2.00- 400 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Anastrozole |
Human |
P |
1.00- 100 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Aripiprazole |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Atazanavir |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Atorvastatin |
Human |
P |
0.250- 100 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Atorvastatin, ortho- hydroxy |
Human |
P |
0.250- 100 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Atorvastatin, para- hydroxy |
Human |
P |
0.250- 100 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Azithromycin |
Human |
P |
0.500- 500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| R |
Bufuralol |
Human (inhibition) |
HM |
0.0250- 1.00 µM |
0.010 |
LC- MS/MS |
N |
| V |
Caffeine |
Human |
P |
25.0- 20,000 ng/mL |
0.100 |
LC- MS/MS |
2, 5 |
| V |
Carboplatin |
Human |
P |
2.00- 2,000 ng/mL |
0.050 |
LC- MS/MS |
6 |
|
Cassette Dosing |
|
|
|
|
|
|
|
3 Compounds |
|
|
|
|
|
|
| R |
Midazolam |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| R |
Dextromethorphan |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| R |
Chlorzoxazone |
Human (inhibition) |
HM |
0.100- 10.0 µM |
0.010 |
LC- MS/MS |
N |
|
5 Compounds |
|
|
|
|
|
|
| R |
Midazolam |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| R |
Dextromethorphan |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| R |
Chlorzoxazone |
Human (inhibition) |
HM |
0.100- 10.0 µM |
0.010 |
LC- MS/MS |
N |
| R |
Coumarin |
Human (inhibition) |
HM |
0.100- 10.0 µM |
0.010 |
LC- MS/MS |
N |
| R |
Tolbutamide |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| V |
Celecoxib |
Human |
P |
5.00- 2,000 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Cetirizine |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Citalopram |
Human |
P |
0.500- 200 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Cortisol |
Human |
U |
1.00- 200 ng/mL |
0.050 |
LC- MS/MS |
N |
| V |
Cortisol |
Human |
U |
1.00- 100 ng/mL |
0.200 |
LC- MS/MS |
N |
| V |
Cortisol |
Human |
U |
3.00- 200 ng/mL |
0.025 |
LC- MS/MS |
N |
| V |
Cotinine |
Human |
P |
10.0- 2,000 ng/mL |
0.250 |
LC- MS/MS |
2 |
| V |
Cyclosporin A |
Human |
WB |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Dapsone |
Human |
P |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Debrisoquine |
Human |
P |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Descarboethoxy Loratadine |
Human |
P |
25.0- 25,000 pg/mL |
0.200 |
LC- MS/MS |
6 |
| V |
Desipramine |
Human |
P |
0.250- 100 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Desmethyl Diazepam |
Human |
P |
1.00- 500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Desmethyl Sertraline |
Human |
P |
0.500- 100 ng/mL |
0.250 |
LC- MS/MS |
6 |
| V |
Desmethyl Sildenafil |
Human |
P |
1.00- 500 ng/mL |
0.100 |
LC- MS/MS |
5, 6 |
| V |
Desmethyl Sildenafil |
Human |
UF |
0.200- 100 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Desmethyl Venlafaxine |
Human |
P |
1.00- 500 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Dexamethasone |
Human |
P |
0.250- 250 ng/mL |
0.100 |
LC- MS/MS |
2, 6 |
| R |
Dextromethorphan |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.005 |
LC- MS/MS |
N |
| V |
Dextromethorphan |
Human |
P |
0.100- 25.0 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Dextromethorphan |
Human |
P |
0.0100- 10.0 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Dextrorphan |
Human |
P |
5.00- 2,500 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Dextrorphan |
Human |
P |
0.300- 300 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Diazepam |
Human |
P |
1.00- 500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Diclofenac |
Human |
P |
5.00- 2,500 ng/mL |
0.050 |
LC- MS/MS |
2 |
| R |
Diclofenac |
Human (inhibition) |
HM |
0.0500- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| V |
Didanosine |
Human |
P |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
6, 2 |
| V |
Digoxin |
Human |
P |
0.100- 10.0 ng/mL |
0.250 |
LC- MS/MS |
2 |
| V |
Digoxin |
Human |
U |
0.500- 100 ng/mL |
0.500 |
LC- MS/MS |
N |
| V |
Diphenhydramine |
Human |
P |
0.500- 200 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Dipyridamole |
Human |
P |
5.00- 3,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Docetaxel |
Human |
P |
10.0- 10,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Donepezil |
Human |
P |
0.500- 250 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Duloxetine |
Human |
P |
0.100- 100 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Efavirenz |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Emtricitabine |
Human |
P |
10.0- 5,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Ethambutol |
Human |
P |
10.0- 5,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Erlotinib |
Human |
P |
2.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2, 6 |
| V |
Ethinyl Estradiol |
Human |
P |
7.50- 500 pg/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Ethinyl Estradiol |
Human |
P |
2.50- 500 pg/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Fluoxetine |
Human |
P |
0.500- 250 ng/mL |
0.100 |
LC- MS/MS |
2, 6 |
| V/C |
Follicle Stimulating Hormone (FSH), TOSOH |
Human |
S |
1.00- 200 miu/mL |
0.400 |
IMMU |
N |
| V |
Gefitinib |
Human |
P |
5.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Gefitinib |
Human |
P |
5.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Gemcitabine |
Human |
P |
50.0- 50,000 ng/mL |
0.050 |
LC- MS/MS |
2, 6 |
| V |
Hydrochlorothiazide |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Hydrocodone |
Human |
P |
0.100- 100 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Hydromorphone |
Human |
P |
0.100- 100 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Hydroxyacid Simvastatin |
Human |
P |
0.100- 25.0 ng/mL |
0.250 |
LC- MS/MS |
2 |
| V |
IL-1β |
Human |
S |
15.0- 5,000 pg/mL |
0.200 |
ECL |
N |
| V |
IL-6 |
Human |
S |
15.0- 5,000 pg/mL |
0.200 |
ECL |
N |
| V |
Indinavir |
Human |
P |
2.00- 400 ng/mL |
0.500 |
LC- MS/MS |
6 |
| V |
Indinavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Iohexol |
Human |
P |
1.00- 500 µg/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Iohexol |
Human |
U |
2.00- 1,000 µg/mL |
0.050 |
LC- MS/MS |
N |
| V |
Ketamine |
Human |
P |
0.500- 500 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Ketoconazole |
Human |
P |
5.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2, 6 |
| V |
Lamivudine |
Human |
P |
2.50- 5,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Lamotrigine |
Human |
P |
25.0- 12,500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Levonorgestrel |
Human |
P |
150- 10,000 pg/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Levonorgestrel |
Human |
P |
50.0- 10,000 pg/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Lopinavir |
Human |
P |
20.0- 20,000 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Lopinavir |
Human |
P |
20.0- 20,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Loratadine |
Dog |
P |
20.0- 20,000 pg/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Loratadine |
Monkey |
P |
20.0- 20,000 pg/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Loratadine |
Rat |
P |
20.0- 20,000 pg/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Loratadine |
Human |
P |
10.0- 1,000 pg/mL |
1.000 |
LC- MS/MS |
6 |
| V |
Loratadine |
Monkey |
DBS |
0.500- 1,000 ng/mL |
0.030 |
LC- MS/MS |
5 |
| V |
Loratadine |
Human |
P |
10.0- 10,000 pg/mL |
0.200 |
LC- MS/MS |
6 |
| V |
Losartan |
Human |
P |
2.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Losartan Carboxylic Acid |
Human |
P |
2.00- 1,000 ng/mL |
0.100 |
LC- MS/MS |
5 |
| R |
Mephenytoin |
Human (inhibition) |
HM |
0.0500- 10.0 µM |
0.010 |
LC- MS/MS |
N |
| V |
Metformin |
Human |
P |
2.00- 2,000 ng/mL |
0.025 |
LC- MS/MS |
6 |
| V |
Methamphetamine |
Human |
P |
0.100- 50.0 ng/mL |
0.250 |
LC- MS/MS |
5 |
| V |
Methotrexate |
Human |
P |
1.00- 250 ng/mL |
0.050 |
LC- MS/MS |
5 |
| V |
Methylphenidate (d-threo-) |
Human |
P |
0.250- 50.0 ng/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Methylphenidate (l-threo-) |
Human |
P |
0.250- 50.0 ng/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Midazolam |
Human |
P |
0.100- 100 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Midazolam |
Human |
P |
0.0500- 50.0 ng/mL |
0.200 |
LC- MS/MS |
6 |
| R |
Midazolam |
Human (inhibition) |
HM |
0.0250- 1.00 µM |
0.015 |
LC- MS/MS |
N |
| V |
Minoxidil |
Human |
S |
0.250- 25.0 ng/mL |
0.100 |
LC- MS/MS |
N |
| V |
Modafinil |
Human |
P |
0.100- 50.0 ug/mL |
0.025 |
LC- MS/MS |
2 |
| V |
Morphine |
Human |
P |
0.500- 50.0 ng/mL |
0.250 |
LC- MS/MS |
3, 5, 6 |
| V |
Morphine-6-β-Glucuronide |
Human |
P |
1.00- 100 ng/mL |
0.250 |
LC- MS/MS |
3, 5, 6 |
| V |
Morphine-3-β-Glucuronide |
Human |
P |
10.0- 1,000 ng/mL |
0.250 |
LC- MS/MS |
3, 5, 6 |
| V |
Moxifloxacin |
Human |
P |
25.0- 5,000 ng/mL |
0.050 |
LC- MS/MS |
3, 5, 6, 7 |
| V |
Moxifloxacin |
Human |
P |
25.0- 5,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Nelfinavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Nicotine |
Human |
P |
1.00- 200 ng/mL |
0.250 |
LC- MS/MS |
2 |
| V |
NNAL, total |
Human |
U |
10.0- 2,500 pg/mL |
2.000 |
LC- MS/MS |
N |
| V |
Norelgestromin |
Human |
P |
50.0- 25,000 pg/mL |
0.500 |
LC- MS/MS |
7 |
| V |
Norketamine |
Human |
P |
0.500- 500 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Noroxycodone |
Human |
P |
0.100- 50.0 ng/mL |
0.400 |
LC- MS/MS |
2 |
| V |
Olanzapine |
Human |
P |
0.250- 100 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Omeprazole |
Human |
P |
0.500- 1,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Ondansetron |
Human |
P |
0.100- 50.0 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Oxycodone |
Human |
P |
0.100- 50.0 ng/mL |
0.400 |
LC- MS/MS |
2 |
| V |
Oxymorphone |
Human |
P |
0.100- 50.0 ng/mL |
0.400 |
LC- MS/MS |
2 |
| V |
Paclitaxel |
Human |
P |
10.0- 2,000 ng/mL |
0.250 |
LC- MS/MS |
2, 6 |
| V |
Paclitaxel |
Human |
P |
10.0- 10,000 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Paraxanthine |
Human |
P |
25.0- 20,000 ng/mL |
0.100 |
LC- MS/MS |
2, 5 |
| V |
Paroxetine |
Human |
P |
0.050.0- 50.0 ng/mL |
0.100 |
LC- MS/MS |
6, 2 |
| R |
Phenacetin |
Human (inhibition) |
HM |
0.150- 5.00 µM |
0.010 |
LC- MS/MS |
N |
| V |
Phentermine |
Human |
P |
0.500- 500 ng/mL |
0.150 |
LC- MS/MS |
2 |
| V |
Pioglitazone |
Rat |
DBS |
5.00- 2,500 ng/mL |
0.020 |
LC- MS/MS |
4 |
| V |
Pioglitazone |
Human |
P |
2.50- 2,500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Platinum |
Human |
P |
1.00- 1,000 ng/mL |
0.100 |
ICP- MS |
5, 6 |
| V |
Platinum |
Human |
PUF |
1.00- 1,000 ng/mL |
0.100 |
ICP- MS |
5, 6 |
| V |
Platinum |
Human |
CSF |
1.00- 1,000 ng/mL |
0.100 |
ICP- MS |
5, 6 |
| V |
Platinum |
Human |
U |
100- 25,000 ng/mL |
0.050 |
ICP- MS |
N |
| V |
Pseudoephedrine |
Human |
P |
5.00- 500 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Pyrazinamide |
Human |
P |
50.0- 25,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Quetiapine |
Human |
P |
0.500- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2, 5, 6 |
| V |
Raltegravir |
Human |
P |
1.00- 1,500 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Ribavirin |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Rifampicin |
Human |
P |
50.0- 35,000 ng/mL |
0.025 |
LC- MS/MS |
1 |
| V |
Ritonavir |
Human |
P |
10.0- 2,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Ritonavir |
Human |
P |
10.0- 2,000 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Ritonavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Ritonavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Ropinirole |
Human |
P |
20.0- 5,000 pg/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Rosiglitazone |
Human |
P |
1.00- 1,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Saquinavir |
Human |
P |
10.0- 10,000 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Scopolamine |
Human |
P |
0.050- 10.0 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Sertraline |
Human |
P |
0.250- 100 ng/mL |
0.250 |
LC- MS/MS |
6 |
| V |
Sildenafil |
Human |
P |
1.00- 500 ng/mL |
0.100 |
LC- MS/MS |
5, 6 |
| V |
Sildenafil |
Human |
UF |
0.200- 100 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Simvastatin |
Human |
P |
0.100- 25.0 ng/mL |
0.250 |
LC- MS/MS |
2 |
| V |
Simvastatin |
Human |
P |
0.0500- 50.0 ng/mL |
0.250 |
LC- MS/MS |
6 |
| V |
Simvastatin Acid |
Human |
P |
0.0500- 10.0 ng/mL |
0.250 |
LC- MS/MS |
6 |
| V |
Sitagliptin |
Human |
P |
0.500- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Sorafenib |
Human |
S |
0.100- 50.0 ng/mL |
0.050 |
LC- MS/MS |
N |
| V |
Sorafenib |
Human |
P |
0.100- 50.0 µg/mL |
0.050 |
LC- MS/MS |
2, 5, 6 |
| V |
Sulfapyridine |
Human |
P |
0.500- 50.0 µg/mL |
0.025 |
LC- MS/MS |
6 |
| V |
Sulfapyridine |
Human |
P |
0.500- 20.0 µg/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Sulfasalazine |
Human |
P |
0.500- 50.0 µg/mL |
0.025 |
LC- MS/MS |
6 |
| V |
Sulfasalazine |
Human |
P |
0.500- 20.0 µg/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Sumatriptan |
Human |
P |
0.200- 200 ng/mL |
0.100 |
LC- MS/MS |
5 |
| V |
Tadalafil |
Human |
P |
1.00- 500 ng/mL |
0.100 |
LC- MS/MS |
6 |
| V |
Tenofovir |
Human |
P |
1.00- 200 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Testosterone |
Human |
S |
20.0- 5,000 ng/dL |
0.500 |
LC- MS/MS |
N |
| V |
Theophylline |
Human |
P |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2, 6 |
| V |
TNF-α |
Human |
S |
5.00- 5,000 pg/mL |
0.050 |
ECL |
N |
| V |
TNF-α |
Human |
S |
15.0- 5,000 pg/mL |
0.200 |
ECL |
N |
| V |
Tolbutamide |
Human |
P |
5.00- 2,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Topiramate |
Human |
P |
0.0200- 20.0 µg/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Triazolam |
Human |
P |
0.100- 50.0 ng/mL |
0.200 |
LC- MS/MS |
5 |
| V |
Valproic Acid |
Human |
P |
0.200- 100 ug/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Vancomycin |
Human |
P |
10.0- 10,000 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Vardenafil |
Human |
P |
0.200- 200 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Venlafaxine |
Human |
P |
1.00- 500 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Vigabatrin |
Human |
P |
0.200- 200 µg/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Vinorelbine |
Human |
P |
0.500- 200 ng/mL |
0.200 |
LC- MS/MS |
2 |
| V |
Voriconazole |
Human |
P |
5.00- 5,000 ng/mL |
0.050 |
LC- MS/MS |
6 |
| V |
Warfarin (R-) |
Human |
P |
5.00- 1,500 ng/mL |
0.250 |
LC- MS/MS |
3 |
| V |
Warfarin (S-) |
Human |
P |
5.00- 1,500 ng/mL |
0.250 |
LC- MS/MS |
3 |
| V |
Zaleplon |
Human |
P |
1.00- 200 ng/mL |
0.050 |
LC- MS/MS |
2 |
| V |
Ziprasidone |
Human |
P |
0.500- 1,000 ng/mL |
0.100 |
LC- MS/MS |
2 |
| V |
Zolpidem |
Human |
P |
1.00- 400 ng/mL |
0.500 |
LC- MS/MS |
2 |
| V |
Zolpidem |
Human |
P |
0.500- 100 ng/mL |
0.150 |
LC- MS/MS |
2, 5, 6, 8 |
|